Fig. 1 · Structure

Documents & Downloads

Pirarubicin

Cat. No. A10735 CAS 72496-41-4

Topoisomerase II inhibitor

Pirarubicin is an analogue of the anthracycline anti-neoplastic doxorubicin. Intercalates into DNA and interacts with Topo II (topoisomerase II) and supressing DNA replication

In Stock

Publications for Pirarubicin

1 publication citing this product

  1. Krishna K Ramajayam, .et al. , Int J Hyperthermia, 2022, 39(1):998-1009 PMID: 35876089

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In UMUC3 and MB49 bladder cancer cells, pirarubicin increased the DNA-damage-associated marker phosphorylated H2A.X after 36 h, alongside increased Akt and Erk1/2 phosphorylation. These findings indicate a cellular damage response accompanied by activation of survival-associated signaling; this experiment does not directly establish topoisomerase-II inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Topo II

Pirarubicin Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Pirarubicin from 2 published references. In vitro models include murine SVR angiosarcoma cells; human UMUC3 and murine MB49 bladder cancer cells.

Pirarubicin In Vitro Studies

A study reporting AdooQ A10735 found that pirarubicin entered SVR angiosarcoma cells more slowly than idarubicin or aclarubicin. Short pirarubicin exposures reduced MTS-based viability in a concentration- and exposure-dependent manner after a 24 h drug-free recovery period. These results describe the tested cell model and exposure schedule, rather than a universal potency value. [2]

Pirarubicin uptake in SVR angiosarcoma cells

Cell-based study · Murine SVR angiosarcoma cells [2]

Intracellular pirarubicin accumulated over the first hour. Uptake was slower than idarubicin and aclarubicin in the same experimental comparison; fitted lines are model predictions, while plotted points are experimental measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell-associated drug extracted and normalized per 10^6 cellsFluorescence-based uptake Uptake over time at 1, 5 and 10 μg/mL; slower than IDA and ACLA (qualitative).[2]

Literature-Reported Treatment Conditions

Treatment concentration
1, 5 and 10 μg/mL
Exposure duration
Sampling during the first 60 min, as plotted in Figure 2
Method
Exposure in complete culture medium at 37°C
Reported limits
The Drugs section allows water or DMSO reconstitution without assigning the solvent to each compound; independent uptake replicate count is not specified in the selected text.
Methods and source locations

Compound reported in the paper: Pirarubicin; Compound label in the paper: PIR

The authors identify AdooQ A10735 as their pirarubicin source. This is historical reported use, not validation of a current lot.

Materials and methods: Cell culture, Drugs, Cellular drug uptake measurements; Results: Cellular drug uptake model; Figure 2a–d

Cell-associated drug extracted and normalized per 10^6 cells: Drug extraction followed by fluorescence at Ex 485/Em 590 nm, calibrated against free drug in the same extraction solution; normalized to counted cells. No curve-derived numerical concentrations adopted. — Figure 2a–d and caption; Cellular drug uptake measurements; Results: Cellular drug uptake model

Short-exposure pirarubicin cytotoxicity in SVR cells

Cell-based study · Murine SVR angiosarcoma cells [2]

Pirarubicin reduced MTS-based viability with increasing concentration and longer exposure. The 15, 60 and 180 min exposure groups belong to one dose–time experiment. Viability was normalized to the 0 μg/mL drug control after a drug-free recovery period.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTS signal relative to the 0 μg/mL controlRelative cell viability Concentration- and exposure-dependent decrease (qualitative; no IC50 assigned).[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 0.001, 0.01, 0.1, 1, 10 and 100 μg/mL
Exposure duration
15, 60 or 180 min exposure, followed by washing and 24 h in drug-free complete medium before the MTS assay
Method
Short exposure followed by recovery; MTS metabolic viability assay
Reported limits
The solvent for pirarubicin is not individually assigned. The 4–6 replicates are wells, not stated independent biological experiments. Table 4 does not specify its IC50 exposure duration or define its ± term, so those numerical potencies are not adopted.
Methods and source locations

Compound reported in the paper: Pirarubicin; Compound label in the paper: PIR

The authors identify AdooQ A10735 as their pirarubicin source. This is historical reported use, not validation of a current lot.

Cell viability assays; Cell cytotoxicity model; Results: Cytotoxicity model; Figure 3c and caption

MTS signal relative to the 0 μg/mL control: MTS absorbance at 490 nm after drug removal/washing and 24 h in fresh medium; no-cell background subtracted; 4–6 wells per condition. Plotted experimental points distinguished from fitted curves. — Cell viability assays; Figure 3c; Cell cytotoxicity model

DNA-damage marker and Akt/ERK responses to pirarubicin

Cell-based study · Human UMUC3 and murine MB49 bladder cancer cells [1]

Pirarubicin treatment increased phosphorylated H2A.X together with Akt and Erk1/2 phosphorylation relative to the zero-drug group. This supports a DNA-damage-associated cellular response accompanied by survival-pathway activation; it is not a direct topoisomerase-II binding or inhibition experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phosphorylated H2A.X, Akt and Erk1/2Western blot response Increased phosphorylation with THP treatment (qualitative); caption: means ± SD, n = 3.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 50, 100 and 200 nM
Exposure duration
36 h
Method
Western blot analysis of treated and zero-THP cells
Vehicle
Stock: DMSO; final solvent-matched control not explicitly described
Reported limits
Final DMSO concentration and whether it was equalized between dose groups are not stated. Direct target occupancy, topoisomerase-II inhibition potency and DNA cleavage were not measured in this adopted experiment.
Methods and source locations

Compound reported in the paper: Pirarubicin; Compound label in the paper: THP

Results concern the paper’s supplier material described as pirarubicin; they do not establish AdooQ lot equivalence or a formulation-independent response.

Reagents; Cell Lines and Culture Conditions; Western Blotting; Results first subsection; Figure 1A–B

Phosphorylated H2A.X, Akt and Erk1/2: Western blotting with β-actin loading control and total Akt/Erk comparators; ImageJ densitometry. Replicate independence is not defined in the caption; no exact fold changes inferred. — Figure 1A–B and caption; Western Blotting; Results: THP Activates Akt and ERK in Addition to Inducing DNA Damage in Bladder Cancer Cells

Pirarubicin In Vivo Studies

In an orthotopic MB49luc bladder-tumor model, intravesical pirarubicin slowed tumor growth and prolonged survival versus PBS. Adding phenformin further improved survival compared with pirarubicin alone. Body-weight loss occurred with pirarubicin, and the combination also showed a smaller weight decline, limiting conclusions about tolerability. [1]

Intravesical pirarubicin and phenformin in an orthotopic bladder-tumor model

Animal study · Female C57BL/6 mice bearing orthotopic MB49luc bladder tumors, with a normal-bladder comparator [1]

Pirarubicin alone slowed tumor growth and prolonged survival versus PBS. Phenformin plus pirarubicin improved survival further. Pirarubicin-associated body-weight loss and residual weight decline with the combination limit a tolerability interpretation; cause of death was not established by these endpoints.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival through day 28Reported survival comparisons Ctrl vs. THP, P = 0.0019; THP vs. THP + phen, P = 0.032.[1]
Tumor-burden imaging and body-weight changeQualitative treatment response Slower tumor growth with THP alone, strongest suppression with combination; THP group lost body weight and combination group also showed a smaller decline.[1]

Conditions shared by the study groups

Route
Intravesical instillation
Frequency
Twice per week
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tumor + PBS control
50 μL PBS per instillation
Tumor-bearing reference groupRapid tumor growth; poorer survival than THP (reported comparison P = 0.0019).[1]
Pirarubicin alone
THP 0.25 mg/mL; 50 μL per instillation
Tumor + PBSTumor growth was slowed and survival prolonged versus PBS (P = 0.0019). Body-weight loss occurred; this does not establish the cause of deaths or general tolerability.[1]
Phenformin alone
Phenformin 1.45 mg/mL; 50 μL per instillation
Tumor + PBS and THP monotherapy comparisonsTumor growth was slowed; the authors report no significant weight loss in this group. This is a comparator, not a pirarubicin monotherapy result.[1]
Pirarubicin + phenformin
THP 0.25 mg/mL + phenformin 1.45 mg/mL; 50 μL per instillation
Each monotherapy and tumor + PBSCombination had the strongest tumor-suppression pattern and longer survival than THP alone (reported P = 0.032). A smaller body-weight decline was still observed. Enhanced combination efficacy is not attributed to THP alone.[1]
Normal bladder comparator
50 μL PBS per instillation
No tumor; reference for bladder size/weightReference for normal bladder appearance and weight; not an antitumor efficacy group.[1]
Tumor + PBS control
Model: Female C57BL/6 mice, 6–8 weeks; orthotopic MB49luc bladder tumors; methods state 12 mice per group
Treatment course: Starting day 2 after tumor implantation, for 2 weeks; survivors followed to day 28
Vehicle: PBS
Reported limits: Intravesical dwell time and final drug-solution vehicle are not specified. Survival-test method is not named; n = 12 is the methods group size, not a separately stated endpoint-specific analyzed n.
Pirarubicin alone
Model: Female C57BL/6 mice, 6–8 weeks; orthotopic MB49luc bladder tumors; methods state 12 mice per group
Treatment course: Starting day 2 after tumor implantation, for 2 weeks; survivors followed to day 28
Reported limits: Intravesical dwell time and final drug-solution vehicle are not specified. Survival-test method is not named; n = 12 is the methods group size, not a separately stated endpoint-specific analyzed n.
Phenformin alone
Model: Female C57BL/6 mice, 6–8 weeks; orthotopic MB49luc bladder tumors; methods state 12 mice per group
Treatment course: Starting day 2 after tumor implantation, for 2 weeks; survivors followed to day 28
Reported limits: Intravesical dwell time and final drug-solution vehicle are not specified. Survival-test method is not named; n = 12 is the methods group size, not a separately stated endpoint-specific analyzed n.
Pirarubicin + phenformin
Model: Female C57BL/6 mice, 6–8 weeks; orthotopic MB49luc bladder tumors; methods state 12 mice per group
Treatment course: Starting day 2 after tumor implantation, for 2 weeks; survivors followed to day 28
Reported limits: Intravesical dwell time and final drug-solution vehicle are not specified. Survival-test method is not named; n = 12 is the methods group size, not a separately stated endpoint-specific analyzed n.
Normal bladder comparator
Model: Female C57BL/6 mice without tumor; methods state 12 mice in each group
Treatment course: PBS instillation comparator in the same study; tumor-relative timing does not apply
Vehicle: PBS
Reported limits: Intravesical dwell time and final drug-solution vehicle are not specified. Survival-test method is not named; n = 12 is the methods group size, not a separately stated endpoint-specific analyzed n.
Methods and source locations

Compound reported in the paper: Pirarubicin; Compound label in the paper: THP

Results concern the paper’s supplier material described as pirarubicin; they do not establish AdooQ lot equivalence or a formulation-independent response.

Orthotopic Implantation and Intravesical Treatment; Statistical Analyses; Results final subsection; Figure 7A–E

Survival through day 28: Daily death monitoring; Kaplan–Meier curves. Methods state 12 mice/group; specific survival-test procedure is not named. No exact survival percentages read from the graph. — Figure 7B and caption; Results: Synergistic Anticancer Activities of Combining Phenformin With THP in Vivo; animal methods

Tumor-burden imaging and body-weight change: IVIS tumor monitoring and daily body weight. Bladder images/weights included mice dying before study end, so terminal measurements were not all at a common time. — Figure 7A, C–E and caption; Results final subsection; animal methods

Tumor + PBS control · Orthotopic Implantation and Intravesical Treatment; Figure 7A–E and caption; Results final subsection

Pirarubicin alone · Orthotopic Implantation and Intravesical Treatment; Figure 7A–E and caption; Results final subsection

Phenformin alone · Orthotopic Implantation and Intravesical Treatment; Figure 7A–E and caption; Results final subsection

Pirarubicin + phenformin · Orthotopic Implantation and Intravesical Treatment; Figure 7A–E and caption; Results final subsection

Normal bladder comparator · Orthotopic Implantation and Intravesical Treatment; Figure 7A–E and caption; Results final subsection

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 72496-41-4
Applications Topoisomerase II inhibitor
Formula C32H37NO12
Molecular Weight 627.64
Synonyms THP-Adriamycin
SMILES
C[C@@H]1[C@@H]([C@@H](C[C@H](O1)OC2C[C@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O[C@@H]6CCCCO6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 6 mg/mL (9.56 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Pirarubicin Research References

  1. [1] Peng M, Deng J, Zhou S, et al. Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth Frontiers in Pharmacology (2019). PMID: 31649535 DOI: 10.3389/fphar.2019.01159 Source material
  2. [2] Ramajayam KK, Newton DA, Haemmerich D. Selecting ideal drugs for encapsulation in thermosensitive liposomes and other triggered nanoparticles International Journal of Hyperthermia (2022). PMID: 35876089 DOI: 10.1080/02656736.2022.2086303 Source material

Publications

1 publication citing this product

  1. Krishna K Ramajayam, .et al. , Int J Hyperthermia, 2022, 39(1):998-1009 PMID: 35876089

Added to your cart

View Cart Checkout
Loading...